PARP1 and prostate cancer: Specifically, BLM inhibition has been shown to enhance the cytotoxic activity of alkylating agents in multiple myeloma and prostate cancer cells [43, 59], and it may offer therapeutic benefit in tumours that are intrinsically resistant to PARP inhibitors or radiation [60].